IR NewsInvestors

Investors
2025 IR News

IR News 2025

Nov 07, 2025

FINANCIALS

FY2025 Q3 Presentation

Nov 07, 2025

FINANCIALS

Consolidated Financial Results for the Third Quarter of the Year Ending December 31, 2025

Nov 04, 2025

ANNOUNCEMENT

Carna announces acceptance of two posters on docirbrutinib for presentation at the 67th ASH Annual Meeting

Aug 06, 2025

FINANCIALS

FY2025 Q2 Presentation

Aug 06, 2025

FINANCIALS

Consolidated Financial Results for the Second Quarter of the Year Ending December 31, 2025

Jun 16, 2025

ANNOUNCEMENT

Docirbrutinib, a next generation BTK inhibitor, demonstrates promising and durable responses in patients with B-cell malignancies in Phase 1b study

May 15, 2025

ANNOUNCEMENT

Carna Announces Upcoming Poster Presentation of Preliminary Results from Ongoing Phase 1b Study of Docirbrutinib, a Non-covalent Pan-mutant BTK Inhibitor, at the European Hematology Association Congress (EHA) 2025

May 09, 2025

FINANCIALS

FY2025 Q1 Presentation

May 09, 2025

FINANCIALS

Consolidated Financial Results for the First Quarter of the Year Ending December 31, 2025

May 01, 2025

ANNOUNCEMENT

Carna presented a poster on monzosertib at AACR Annual Meeting

Mar 27, 2025

ANNOUNCEMENT

Carna announces an upcoming poster presentation at AACR Annual Meeting

Mar 19, 2025

ANNOUNCEMENT

Carna Announces to Extend the Agreement with Sumitomo Pharma on Joint Research, Development, and Commercialization of Kinase Inhibitors

Feb 10, 2025

ANNOUNCEMENT

Corporate Presentation Feb. 2025

Feb 10, 2025

FINANCIALS

FY2024 Presentation

Feb 10, 2025

FINANCIALS

Consolidated Financial Results for the Year Ended December 31, 2024